HUANGSHAN-TOURISM
8.3.2024 03:41:31 CET | Business Wire | Press release
Incorporated tourism contents from not only Mount Huangshan itself, but also with attractions in its neighborhood, the Grand Huangshan region made its debut at ITB Berlin 2024, the world’s leading travel trade show with over 5,500 exhibitors from 170 countries and regions, which concluded in Berlin on Thursday.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240307230072/en/
Famous scenery such as pine trees, cloud seas, peculiarly-shaped stone peaks of Mount Huangshan in East China's Anhui province. (Photo: Business Wire)
Located in East China's Anhui province, Mount Huangshan, also known as the Yellow Mountain, is famous for its pine trees, cloud seas, peculiarly-shaped stone peaks, hot springs and winter snow scenery. With its natural and cultural values well interconnected, Huangshan was inscribed on the UNESCO World Cultural and Natural Heritage List in 1990.
This year marks the fifth consecutive participation of Huangshan Tourism Co., Ltd. (HSTD) in the ITB. Compared to the conventionally produced booths of previous years, HSTD innovatively designed its booth with the theme of the world-class leisure and wellness tourism destination, the Grand Huangshan region, this time.
They incorporated elements from tourist attractions, intangible cultural heritage skills, and traditional Huizhou cuisine of the four core cities in the Grand Huangshan region: Huangshan, Anqing, Chizhou, and Xuancheng. The booth featured a backdrop of traditional Chinese landscape paintings, adorned with simplified drawings of Huizhou-style architectural features, presenting a fresh image to exhibitors and visitors from around the world.
Meanwhile, a series of introduction material like visitor's guide and creative designed souvenirs have been distributed during the event. And the Grand Huangshan regional tourism resources, Huizhou cultural characteristics and high-quality international tourist routes were introduced at ITB as well, inviting international guests.
Many visitors expressed that they looked forward to having the opportunity to visit Huangshan and will introduce the beautiful scenery of Huangshan to more people.
According to HSTD, it’s already the second splendid appearance on the international stage for Huangshan, after the London Trafalgar Square Chinese New Year Celebration event early in February. It is also a significant step in implementing Huangshan City's global promotion plan for the urban brand "Creative Huangshan, Beauty in Huizhou."
In recent years, Huangshan Tourism has been dedicated to international exchange, cooperation, and brand promotion. It has actively participated in internationally influential cultural and tourism exchange events such as the New York Asian Cultural Festival, the United Nations "Journey Through Civilizations" photo exhibition, and the New York "Chinese Night."
Simultaneously, there has been a continuous increase in efforts to promote the brand worldwide, showcasing the tourism resources and cultural heritage of the beautiful Huangshan to overseas residents and tourists through multi-dimensional, comprehensive, and close-range approaches.
According to Huangshan, it will continue to spare no effort in showcasing the image of the Huangshan to international tourists in a fresh and compelling way and enhancing the visibility and influence of Grand Huangshan region as an international famous tourism destination.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240307230072/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom